AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
ROCKVILLE, Md. May 8, 2026 /PRNewswire=YONHAP/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the ...
Epicrispr Biotechnologies ("Epicrispr"), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics ( ...
Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference ID# 8879216 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic ...
PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...
Latus Bio has raised $97 million in Series A funding, including a $43 million extension led by 8VC, to speed development of its gene therapies for rare diseases. The capital will support Huntington’s ...
With gene therapy rapidly shifting from orphan to prevalent indications, the demand for viral vectors is surging—especially for adeno-associated virus (AAV). Yet the industry is still primarily ...
Latus Bio has secured $97 million in Series A financing, including a $43 million extension led by 8VC, to advance and broaden access to its gene therapies. The funding will support clinical milestones ...
Circio Holding announces, it is presenting new and confirmatory in vivo data for its circVec-AAV expression platform. The in vivo results show, for the first time, up to 50-fold enhanced AAV-circVec ...
CRISPR–Cas9 delivery by adeno-associated virus (AAV) holds promise for gene therapy but faces critical barriers on account of its potential immunogenicity and limited payload capacity. Here, we ...
AAVnerGene Inc. today announced the launch of AAVone2.1, the next-generation evolution of its proprietary AAVone single-plasmid AAV production ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results